Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Foreword - p. xiii 8. Preface - p. xv 9. Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient? - p. 315 10. Should Methotrexate Have Any Place in the Treatment of Psoriatic Arthritis? - p. 325 11. Is There a Role for MRI to Establish Treatment Indications and Effectively Monitor Response in Patients with Axial Spondyloarthritis? - p. 341 12. Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate? - p. 359 13. Should Generalized Immunosuppression or Targeted Organ Treatment be the Best Principle for Overall Management of Systemic Lupus Erythematosus? - p. 369 14. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide? - p. 379 15. Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology? - p. 399 16. Should Platelet-Rich Plasma or Stem Cell Therapy Be Used to Treat Osteoarthritis? - p. 417 17. Intra-articular Hyaluronan Therapy for Symptomatic Knee Osteoarthritis - p. 439 18. Vascular Consequences of Hyperuricemia and Hypouricemia - p. 453 19. Are There Benefits and Risks to Biosimilars from a Patient Perspective? - p. 465
No hay muestra disponible
No hay ficha técnica disponible
Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Foreword - p. xiii 8. Preface - p. xv 9. Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient? - p. 315 10. Should Methotrexate Have Any Place in the Treatment of Psoriatic Arthritis? - p. 325 11. Is There a Role for MRI to Establish Treatment Indications and Effectively Monitor Response in Patients with Axial Spondyloarthritis? - p. 341 12. Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate? - p. 359 13. Should Generalized Immunosuppression or Targeted Organ Treatment be the Best Principle for Overall Management of Systemic Lupus Erythematosus? - p. 369 14. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide? - p. 379 15. Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology? - p. 399 16. Should Platelet-Rich Plasma or Stem Cell Therapy Be Used to Treat Osteoarthritis? - p. 417 17. Intra-articular Hyaluronan Therapy for Symptomatic Knee Osteoarthritis - p. 439 18. Vascular Consequences of Hyperuricemia and Hypouricemia - p. 453 19. Are There Benefits and Risks to Biosimilars from a Patient Perspective? - p. 465
No hay muestra disponible
No hay ficha técnica disponible
